Organogenesis Holdings Inc (ORGO)vsUnited Therapeutics Corporation (UTHR)
ORGO
Organogenesis Holdings Inc
$2.44
+1.24%
HEALTHCARE · Cap: $317.74M
UTHR
United Therapeutics Corporation
$541.60
+1.84%
HEALTHCARE · Cap: $23.74B
Smart Verdict
WallStSmart Research — data-driven comparison
United Therapeutics Corporation generates 464% more annual revenue ($3.18B vs $564.17M). UTHR leads profitability with a 41.9% profit margin vs 6.6%. ORGO trades at a lower P/E of 16.5x. UTHR earns a higher WallStSmart Score of 67/100 (B-).
ORGO
Strong Buy67
out of 100
Grade: B-
UTHR
Strong Buy67
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+46.7%
Fair Value
$7.02
Current Price
$2.44
$4.58 discount
Margin of Safety
+62.9%
Fair Value
$1282.02
Current Price
$541.60
$740.42 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Revenue surging 78.1% year-over-year
Attractively priced relative to earnings
Strong operational efficiency at 28.9%
Keeps 42 of every $100 in revenue as profit
Strong operational efficiency at 45.0%
Safe zone — low bankruptcy risk
Earnings expanding 24.5% YoY
Areas to Watch
Smaller company, higher risk/reward
6.6% margin — thin
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : ORGO
The strongest argument for ORGO centers on Price/Book, Revenue Growth, P/E Ratio. Revenue growth of 78.1% demonstrates continued momentum.
Bull Case : UTHR
The strongest argument for UTHR centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 41.9% and operating margin at 45.0%.
Bear Case : ORGO
The primary concerns for ORGO are Market Cap, Profit Margin.
Bear Case : UTHR
The primary concerns for UTHR are PEG Ratio.
Key Dynamics to Monitor
ORGO profiles as a hypergrowth stock while UTHR is a mature play — different risk/reward profiles.
ORGO carries more volatility with a beta of 1.39 — expect wider price swings.
ORGO is growing revenue faster at 78.1% — sustainability is the question.
UTHR generates stronger free cash flow (173M), providing more financial flexibility.
Bottom Line
ORGO scores higher overall (67/100 vs 67/100) and 78.1% revenue growth. UTHR offers better value entry with a 62.9% margin of safety. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Organogenesis Holdings Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures and markets solutions for the advanced wound care and surgical and sports medicine markets in the United States. The company is headquartered in Canton, Massachusetts.
United Therapeutics Corporation
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
United Therapeutics Corporation, a biotechnology company, is dedicated to the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company is headquartered in Silver Spring, Maryland.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?